GRGuilherme Piovezani Ramos

Guilherme Piovezani Ramos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guilherme Piovezani Ramos has a total of 134 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA

    by Guilherme Piovezani Ramos, Daniel Zeve, Amy Shepherd, Elisa Saint-Denis, Olivia Alderfer, Bia Frintu, Stanley Dale, Karina Sharma, Emma Mohlmann, Prabhath Mannam, et al.

    Enteroendocrine cells (EECs) are specialized sensors of the gastrointestinal (GI) epithelium that regulate gut function and systemic metabolism through hormone secretion. The molecular pathways directing intestinal stem cell (ISC) differentiation into EECs are incompletely understood due, in part, to their rarity. We sought to identify novel regulators of human EEC differentiation using a high-throughput screen of FDA-approved drugs and human duodenal organoids. Two epidermal growth factor receptor inhibitors (EGFRi) commonly used in cancer therapy and known to cause GI side effects, erlotinib and lapatinib, emerged as strong inducers of EEC differentiation, dramatically increasing chromogranin A (CHGA) expression compared to controls, while maintaining ISC function and organoid growth. EGFRi-treated organoids revealed robust and broad upregulation of EEC hormones, including serotonin (5HT), motilin (MLN), and somatostatin (SST), among others. In agreement with these findings, analysis of a patient cohort with lung cancer revealed an association with erlotinib use and increased circulating levels of the above EEC hormones compared to matched controls. Supporting a direct effect of EGFRi on EEC differentiation, mice treated with erlotinib demonstrated increased EEC numbers and hormones and showed EGFRi-associated diarrhea (EAD), a limiting side effect of these medications. Mechanistically, EGFRi induced upregulation of interferon (IFN) signaling targets during early ISC-to-EEC differentiation. Consistent with this, inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) attenuated EGFRi-induced EEC differentiation. These findings provide important insight into EEC differentiation that could inform treatment strategies for EAD, metabolic diseases, and GI diseases. Brief Summary: Inhibition of EGFR signaling promotes human ISC-to-EEC differentiation through activation of STAT1 signaling.

  • Open Access

    Enteroendocrine cell differentiation: Implications for human disease

    by Elisa Saint-Denis, Bianca Frintu, Madelyn Goldsmith, Guilherme P. Ramos, Daniel Zeve


  • G9a Modulates Lipid Metabolism in CD4 T Cells to Regulate Intestinal Inflammation

    by Guilherme Piovezani Ramos, Adebowale O. Bamidele, Emily E. Klatt, Mary R. Sagstetter, Ahmed T. Kurdi, Feda H. Hamdan, Robyn Laura Kosinsky, Joseph M. Gaballa, Asha Nair, Zhifu Sun, et al.


  • High-Fiber Diet

    by Gian Marco Giorgetti, Annarita Eramo, Valeria Clemente, Guilherme Piovezani Ramos, Odery Ramos


  • Mo1522: MULTICENTER REAL-WORLD EXPERIENCE OF USTEKINUMAB TROUGH LEVELS AND ANTIBODIES IN CROHN’S DISEASE MAINTENANCE THERAPY

    by Guilherme Piovezani Ramos, Vivek Tharayil, Ahmed T. Kurdi, Aman S. Bali, Stacey C. Rolak, Thomas W. Fredrick, Manuel B. Braga Neto, Daniela Guerrero Vinsard, Siri A. Urquhart, Katie A. Dunleavy, et al.

  • Open Access

    Clinical Course and Impact of Immune Checkpoint Inhibitor Colitis Resembling Microscopic Colitis

    by Thomas W Fredrick, Guilherme P Ramos, Manuel B Braga Neto, Sunanda Kane, William A Faubion, Edward V Loftus, Darrell S Pardi, Shabana F Pasha, Francis A Farraye, Lizhi Zhang, et al.

    Background: Microscopic colitis (MC) is suspected to result from increased immune activity in gut mucosa. Immune checkpoint inhibitors (ICIs) treat cancer by activating the immune system, and further investigation is needed regarding their role in the development of MC. Methods: A retrospective case series investigated cases of endoscopically and histologically confirmed MC developing after administration of ICIs. Clinical notes and medication administration records were reviewed for demographics, symptom duration, and treatment response. Results: Nineteen cases of de novo MC were identified, with 95% of cases requiring steroid treatment, 53% presenting with hospitalization, and colitis-related mortality in 1 individual. Symptom onset occurred a median of 160 days after initiation of ICI therapy and 53 days after their most recent dose of therapy. Patients had a median of 125 days of symptoms, and ICI therapy was held in 70% of individuals due for treatment. Conclusions: MC can develop after ICI administration, and presents with severe symptoms, often requiring hospitalization and steroid treatment. In certain individuals this can require a prolonged treatment course of steroid therapy or immunomodulators. Individuals developing diarrhea after ICI therapy warrant thorough workup including endoscopy and rapid treatment initiation given the disease severity observed in this series.


  • BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease

    by Michelle M. Gonzalez, Adebowale O. Bamidele, Phyllis A. Svingen, Mary R. Sagstetter, Thomas C. Smyrk, Joseph M. Gaballa, Feda H. Hamdan, Robyn Laura Kosinsky, Hunter R. Gibbons, Zhifu Sun, et al.

    FOXP3+ Tregs are expanded within the inflamed intestine of human Crohn’s disease, yet FOXP3-mediated gene repression within these cells is lost. The polycomb repressive complexes play a role in FOXP3 target gene regulation, but deeper mechanistic insight is incomplete. We have now specifically identified the polycomb-repressive complex 1 (PRC1) family member, BMI1 in the regulation of a proinflammatory enhancer network in both human and murine Tregs. Using human Tregs and lamina propria T cells, we inferred PRC1 to regulate Crohn’s associated gene networks through assays of chromatin accessibility. Conditional deletion of BMI1 in murine FOXP3+ cells led to systemic inflammation. BMI1-deficient Tregs beared a TH1/TH17-like phenotype as assessed by assays of genome wide transcription, chromatin accessibility and proteomic techniques. Finally, BMI1 mutant FOXP3+ cells did not suppress colitis in the adoptive transfer model of human inflammatory bowel disease. We propose that BMI1 plays an important role in enforcing Treg identity in vitro and in vivo. Loss of Treg identity via genetic or transient BMI1 depletion perturbs the epigenome and converts Tregs into Th1/Th17-like proinflammatory cells, a transition relevant to human Crohn’s disease associated CD4+ T cells.


  • Open Access

    Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience

    by Guilherme Piovezani Ramos, Badr Al-Bawardy, Manuel Bonfim Braga Neto, Adam C Bledsoe, Kevin P Quinn, Valérie Heron, Maria Alice V Willrich, Amanda Johnson, Victor G Chedid, Nayantara Coelho-Prabhu, et al.

    Background: Certolizumab pegol (CZP) has been successfully used for the treatment of Crohn disease (CD); however, real-world data regarding the utility of CZP trough levels (CTLs) are lacking. We aimed to correlate CTL with CD outcomes and to determine frequency of CZP antibodies. Methods: Retrospective evaluation of all CD patients on maintenance CZP with CTL obtained between 2016 and 2019. Outcomes included: median CTL, presence of anti-CZP antibodies, biochemical response (BR), clinical response (CR), radiologic response (RR), radiologic healing (RH), and mucosal healing (MH). Results: Seventy-seven CD patients were included. Median CTL was 18.9 µg/mL (interquartile range, 7.6–35.4). Twenty-three patients (27.3%) had positive antibody levels, with lower median CTL compared to patients with no antibodies (0.0 vs 29.8; P < 0.0001). Median CTL levels were higher in patients with vs without CR (30.4 vs 10.3 µg/mL; P = 0.0015) and RR (29.6 vs 5.8 µg/mL; P = 0.006). CZP dosing at least every 2 weeks was associated with higher odds of achieving MH (odds ratio, 3.2; 95% confidence interval, 1.03–9.97). CTL resulted in change in clinical management in 62.7% of cases and presence of CMZ antibodies was associated with an odds ratio of 5.83 (95% confidence interval, 1.57–21.73) of change in management. Receiver operating characteristic curve and quartile analysis suggested that CTL >19 µg/mL is associated with increased rates of CR and RR. Conclusions: Higher CTL was significantly associated with CR and RR. The rate of CZP antibodies was 27.3%. Our data suggest maintenance CTL of ≥19 µg/mL should be achieved in order to optimize outcomes in clinical practice.


  • CRYPTOGENIC MULTIFOCAL ULCEROUS STENOSING ENTERITIS (CMUSE): A 20-YEAR SINGLE CENTER CLINICAL AND RADIOLOGIC EXPERIENCE

    by Guilherme Piovezani Ramos, David Bartlett, Adam Bledsoe, David Bruining, Jeff Fidler, Shannon Sheedy, Joseph Murray